ANKRD26突变所致遗传性血小板减少症被误诊并治疗为骨髓增生异常综合征:两例报告
本文报告两例无血缘关系的血小板减少症患者,骨髓检查发现巨核细胞发育异常,被误诊为骨髓增生异常综合征(MDS,难治性血小板减少)并接受多疗程5-阿扎胞苷治疗,后经家系调查发现血小板减少而分子诊断為血栓性血小板减少症2型(THC2)。作者强调,对于孤立性血小板减少伴巨核细胞发育异常的患者,应始终考虑遗传性疾病。
要点
- THC2为常染色体显性遗传病,由ANKRD26基因5'UTR点突变引起。
- THC2患者有先天性血小板减少、血小板形态和功能正常及巨核细胞发育异常。
- 两例患者因骨髓巨核细胞发育异常被误诊为MDS并接受5-阿扎胞苷治疗,后经家系调查确诊THC2。
核心结论
- THC2患者存在被误诊为MDS并接受不当骨髓抑制治疗的风险。
- 当患者表现为孤立性血小板减少和巨核细胞发育异常时,必须考虑遗传性疾病,因为巨核细胞发育异常也是其他类型遗传性血小板减少症的特征。
研究设计与样本
- 本文为两例病例报告,描述了两例无血缘关系的血小板减少症患者,分别就诊于两家不同机构。
主要发现
- 两例患者骨髓检查均发现巨核细胞发育异常,被诊断为骨髓增生异常综合征(MDS,难治性血小板减少),并接受多疗程5-阿扎胞苷治疗。
- 随后,在家系中发现血小板减少,最终在两个家系中均获得THC2的分子诊断。
关键数值与推荐
- THC2由ANKRD26基因5'UTR点突变引起,为常染色体显性遗传病。
- THC2患者表现为先天性血小板减少、血小板形态和功能正常及巨核细胞发育异常。
临床怎么用
- 作者指出,对于孤立性血小板减少伴巨核细胞发育异常的患者,应始终考虑遗传性疾病。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Thrombocytopenia 2 (THC2) is an inherited thrombocytopenia (IT) with dysmegakaryopoiesis. Physicians often do not suspect the genetic origin of thrombocytopenia in patients with THC2. We report two THC2 patients misdiagnosed with myelodysplasia and treated with chemotherapy. IT should be always considered in patients with isolated thrombocytopenia and dysmegakaryopoiesis. SUMMARY: Thrombocytopenia 2 (THC2) is an autosomal-dominant disorder caused by point substitutions in the 5'UTR of the ANKRD26 gene. Patients have congenital thrombocytopenia, normal platelet morphology and function, and dysmegakaryopoiesis. Thrombocytopenia is frequently discovered only in adulthood and physicians often do not suspect its genetic origin. We describe two unrelated patients referred to two different institutions for investigation of thrombocytopenia. Based on the finding of dysmegakaryopoiesis at bone marrow examination, patients were diagnosed with myelodysplastic syndrome (MDS) (refractory thrombocytopenia) and treated with several courses of 5-azacytidine. Subsequently, demonstration of thrombocytopenia in their relatives eventually led to molecular diagnosis of THC2 in both families. These cases highlight that patients with THC2 are at risk of being misdiagnosed with MDS and receiving undue myelosuppressive treatments. Because dysmegakaryopoiesis is a feature also of other forms of inherited thrombocytopenia, a genetic disorder must always be considered when a patient presents with isolated thrombocytopenia and dysmegakaryopoiesis.
引用
- Zaninetti C, Santini V, Tiniakou M, et al. Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases. J Thromb Haemost. 2017. PMID: 28976612. doi:10.1111/jth.13855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。